The Dose of INGREZZA (valbenazine) Capsules in Patients With Hepatic Impairment

Thank you for contacting Neurocrine Biosciences with your unsolicited Medical Information request regarding the dose of INGREZZA (valbenazine) capsules in patients with hepatic impairment.

INGREZZA is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.

The INGREZZA Full Prescribing Information states that “the recommended dose for patients with moderate or severe hepatic impairment (Child-Pugh score 7 to 15) is INGREZZA 40 mg once daily.

Patients with moderate to severe hepatic impairment (Child-Pugh score between 7 and 15) had higher exposure of valbenazine and its active metabolite than patients with normal hepatic function.”

This letter and the enclosed material are provided in response to your unsolicited medical information inquiry. Please feel free to contact Neurocrine Medical Information at (877) 641-3461 or medinfo@neurocrine.com if you would like to request additional information.

Enclosures:

1. INGREZZA [package insert]. Neurocrine Biosciences, Inc., San Diego, CA; 2017
2. Important Safety Information. Neurocrine Biosciences, Inc., San Diego, CA; 2017

 

MED-MI-TD-US-0031

Need to get in touch with us?

medinfo@neurocrine.com
1-877-641-3461